Versartis' IPO

Versartis raised a round of funding on March 21, 2014. Investors include Public.

Versartis is a biotechnology company developing therapeutics for the treatment of endocrine disorders. The company's lead product candidate is VRS-317, a once monthly form of human growth hormone. Ver…

Articles about Versartis' IPO: